#TNGX↓

TNGX/ 02/23/2026 · 10:51 AM

2026 Could Be Huge: Mizuho Predicts Major Stock Surge for Tango Therapeutics on Phase 1 Data

Mizuho starts coverage on Tango Therapeutics with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung.

TNGX/ 12/04/2025 · 11:24 AM

Stifel Begins Coverage of Tango Therapeutics with Bullish Outlook

Stifel initiates coverage of Tango Therapeutics with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035.